The speed of biosensor advancements for prostate cancer testing enables useful features for early diagnosis and individualized monitoring, as well as personalized treatment plans. To become clinically available, these biosensors must successfully navigate the challenging regulatory approval process. This section offers a detailed analysis of the various regulatory structures that control biosensor development while discussing fundamental frameworks from the U.S. Food and Drug Administration, the European Medicines Agency, and other worldwide organizations. The narrative encompasses device classification rules, clinical validation requirements, ethical/legislative obligations, as well as artificial intelligence-based biosensor assessment protocols and post-market monitoring tasks to ensure both safety and effectiveness. The discussion focuses on new regulatory patterns and the software as a medical device approach, in addition to risk-driven device grouping. The discourse outlines the need for regulatory jurisdictions to align, and it discusses the distinctive requirements of biosensors that utilize machine learning and nanotechnology features. Illustrative analyses of approved prostate cancer biosensors demonstrate successful regulatory approaches by explaining the difficulties and methods to overcome them through real-world observations. The final segments of this work present predictions about patient-centered regulatory science jointly developed with global partners and continuous learning frameworks. Policy and compliance play a crucial role in enabling safe and effective biosensor technologies to reach patients worldwide through their combined efforts with scientific innovation.